Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Shiro Takekawa

Nobuhiro Suzuki

Yuji Ishihara

Jun Terauchi

Masaaki Mori

Makoto Kamata

Kaneyoshi Kato

Taiji Asami

Naoki Nishizawa

Kazuyoshi Aso

Ayumu Niida

Yukio Shimomura

Mari Adachi

Yoko Kanematsu

Tomoko Morimoto

Chieko Kitada

Hiroyuki Watanabe

Tetsuo Miwa

Satoshi Endo

Naoki Tarui

Tsukasa Sugo

Yoshihiro Ishibashi

Koki Kato

Takashi Santo

The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided.P-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P&#x2003;&#x2003; (I)wherein each symbol is as defined herein.

Peptide compound

The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. wherein each symbol is as defined herein.

The present invention provides a compound represented by the formula or salts thereof, wherein, Ar, Ar, R, R, R, Ra, Ra, Ra, Raand Y have meanings described in the specification, having a melanin-concentrating hormone antagonistic, action and useful as an agent for the prophylaxis or treatment of obesity and the like.

Amine derivative

A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; Rand Rare the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or Rand R, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

Melanin-concentrating hormone antagonist

A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein

Quinoline compound

A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Aris a cyclic group which may have substituents;

Melanin concentrating hormone antagonist

A novel biphenyl compound having GPR 14 antagonistic activity. It is a compound represented by the formula (I): wherein Rrepresents hydrogen, etc.; X represents 1 to 12 spacers; A represents amino, etc., Rand Reach represents a hydrocarbon group, etc.; and rings B and C each represents an optionally further substituted benzene ring, or a salt thereof.

Biphenyl compound

The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, and the like, and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, and the like, but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Wili syndrome and the like.

Antiobestic agents methods for screening antiobestic agents and kits comprising same

A melanin-concentrating hormone antagonist comprising a compound of the formula (I):wherein Aris a cyclic group which may be substituted; X and Y are the same or different and are a spacer having a main chain of 1 to 6 atoms; Ar is a condensed polycyclic aromatic ring which may be substituted; Rand Rare the same or different and are hydrogen atom or a hydrocarbon group which may be substituted; or Rand R, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or R, together with the adjacent nitrogen atom, Y and Ar, may form a condensed ring; or a salt thereof is useful as an agent for preventing or treating obesity, etc.

The present invention provides a compound of the formula:

Growing community of inventors

Nishinomiya, Japan

Shiro Takekawa